Results released
Open the filing on sec.gov
Grace Therapeutics, Inc. (GRCE)
Nasdaq: GRCE · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 2008
The companyfiscal 2022, as filed
Revenue$0.00-100.0%
Net income-$9.8M+50.1%
Earnings per share$-1.62
Operating cash flow-$17.2M-20.4%
Cash$30.3M-40.4%
Debtn/a
Shareholders’ equity$108M+94.5%
Shares, diluted6,140,294
Return on equity-12.2%
The recordfrom its filings
Filings in 202653
Newest filingNov 12 · 8-K
Annual reportJun 18, 2026
Quarterly reportNov 12, 2026
Next report due10-Q by Feb 14
Insider sales, 12 months$0.00
Insider buys, 12 months$200,000
Patents granted1
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$21.4MCash from operations -$8.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.